With close to one million downloads, Shotsy is the most popular GLP-1 tracking app on the market, and now meets patients at ...

Managing complex medical conditions often requires the simultaneous use of multiple different drugs, referred to as polypharmacy. While necessary, this significantly increases the risk of drug-drug ...

FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A U.S. court has certified a nationwide class of third party payors in racketeering litigation tied to the diabetes drug Actos. The class includes U.S. insurers and other payors that reimbursed for ...

SINGAPORE – The temporary listing of etomidate as a Class C drug has been extended till April 30. According to a legislative supplement published in the Government Gazette on Feb 26, the regulations ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

For the more than 48 million Americans with substance use disorders, including a disproportionate share of veterans, GLP-1 drugs are not yet an approved addiction treatment. But the evidence base is ...

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy weight-loss drugs.

Yet American health care has in the past proved resistant to treatment from disrupters. In 2008 Google, a search colossus, ...

Wolfe said the oral GLP-1 therapy could broaden the obesity treatment market because it combines strong weight-loss results ...

A coalition of law enforcement and anti-drug groups is calling on congressional leaders to oppose efforts to delay the implementation of a law that’s set to recriminalize most hemp THC products within ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...